ClinicalTrials.gg
CompletedNCT04722653Updated Apr 5, 2022

A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men

A Phase 1 interventional study of NNC0194-0499 and Placebo (NNC0194-0499 ) in Non-alcoholic Steatohepatitis, sponsored by Novo Nordisk A/S. Completed at 1 site in Japan. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-05.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S — 1 open to participants now, 4 under way, 3 of them phase 3. Non-alcoholic Fatty Liver Disease · Novo Nordisk A/S.

Enrollment
12th of 17
42 · median 71
Started
2021
with 4 others
Phase 1
7 of 18
none open now
Registered
6th of 18
by date

Among the 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S, this one is the 12th largest by enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2021, is one of 7 in phase 1, and was the 6th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

1 of the 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 20 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Non-alcoholic Fatty Liver Disease by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study looks at how a new medicine called NNC0194-0499 works in the body of Japanese men and non-Asian men.

Japanese participants will either get NNC0194-0499 or placebo - which treatment participants get is decided by chance. Non-Asian participants will get NNC0194-0499.

Participants will get 1 or 2 injections of the study medicine. It will be injected with a needle into a skin fold on the stomach.

The study will last for a maximum of 66 days. Participants will have 8 scheduled visits with the study doctor. For 1 of the visits participants will stay at the clinic for 6 days (5 nights).

The study includes blood sampling. Participants will not be able to take part in the study if the study doctor thinks there is a risk for participants health.

03

Conditions studied

  • Non-alcoholic Steatohepatitis
04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male, aged 20-55 years (both inclusive) at the time of signing
  • For Japanese subjects only, both parents of Japanese descent. For non-Asian subjects only, both parents of non-Asian descent
  • (BMI) between 23.0 and 34.9 kg/m\^2 (both inclusive)
  • Body weight greater than or equal to 60 kg

Exclusion criteria

Exclusion Criteria:

  • Any disorder which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol
  • Subjects aged above or equal to 40 years with an estimated 10-year atherosclerotic cardiovascular disease risk (as described in the American College of Cardiology and the American Heart Association Prevention Guideline) greater than or equal to 5 percentage
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    NN0194-0499

    Japanese participants will be randomised 3:1 to receive either a single dose of NNC0194-0499 or placebo, Asian participants will only receive NNC0194-0499. There will be 3 cohorts with escalating dose levels. There should be at least 4 days between dose administration of the last participant in a dose level cohort and dose administration of the first participant in the following dose level cohort.

    Drug: NNC0194-0499

  • Placebo comparator
    Placebo

    Japanese participants will be randomised 3:1 to receive either a single dose of NNC0194-0499 or placebo.

    Drug: Placebo (NNC0194-0499 )

Interventions

  • 1 single dose administered subcutaneously (s.c. - under the skin)

  • DrugPlacebo (NNC0194-0499 )

    1 single dose administered subcutaneously (s.c. - under the skin).

06

What researchers measure

Primary outcomes

  1. Number of treatment emergent adverse events (TEAEs)

    Count of events

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment period at follow-up (Day 36)

Secondary outcomes

  1. AUC0-∞, SD: The area under the NNC0194-0499 serum concentration-time curve from time 0 to infinity after a single s.c.(subcutaneous) administration

    h·nmol/L

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

  2. AUC0-tz, SD: The area under the NNC0194-0499 serum concentration-time curve from time 0 to the time of the last quantifiable sample after a single s.c. administration

    h·nmol/L

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

  3. AUC0-168h, SD: The area under the NNC0194-0499 serum concentration-time curve from time 0 to 168 hours after a single s.c. administration

    h·nmol/L

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

  4. Cmax, SD: Maximum concentration of NNC0194-0499 in serum after a single s.c. administration

    nmol/L

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

  5. tmax, SD: Time from dose administration to maximum serum concentration of NNC0194-0499 after a single s.c. administration

    Hours

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

  6. t½, SD: Terminal half-life of NNC0194-0499

    Hours

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

  7. CL/FSD: Apparent total serum clearance of NNC0194-0499

    L/h

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

  8. Vz/FSD: Apparent volume of distribution of NNC0194-0499 in the terminal phase

    L

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

  9. MRTSD: The mean residence time of NNC0194-0499 after a single s.c. administration

    Hours

    Time frame: From Day 1 (pre-dose) until completion of the post-treatment follow-up visit (Day 36)

07

Study locations

1 site
  • Novo Nordisk Investigational Site
    Tokyo, 130-0004, Japan
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Apr 2021, 2 months.

Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 2 months is below that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2021
First posted
Jan 25, 2021
StartActual
Feb 2, 2021
Primary completionActual
Apr 27, 2021
CompletionActual
Apr 27, 2021
Last update
Apr 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04722653
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 25, 2021
Start date
Feb 2, 2021
Primary completion
Apr 27, 2021
Completion
Apr 27, 2021
Last update
Apr 5, 2022

Study contacts

Clinical Transparency (dept. 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zalfermin

Start the discussion